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Edited by Horst FeldmannAbstract One of the major problems in chemotherapy is multi-
drug resistance (MDR) against anticancer drugs. ATP-binding
cassette (ABC) transporters are a family of proteins that medi-
ate MDR via ATP-dependent drug eﬄux pumps. Many MDR
inhibitors have been identiﬁed, but none of them have been pro-
ven clinically useful without side eﬀects. Eﬀorts continue to dis-
cover not toxic MDR inhibitors which lack pharmacokinetic
interactions with anticancer drugs. Novel approaches have also
been designed to inhibit or circumvent MDR. In this review,
the structure and function of ABC transporters and development
of MDR inhibitors are described brieﬂy including various ap-
proaches to suppress MDR mechanisms.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Multidrug resistance; ATP-binding cassette
transporters; Cancer chemotherapy; Multidrug resistance
inhibitors1. Introduction
The failure of the curative treatment of cancer patients often
occurs as a result of intrinsic or acquired drug resistance of the
tumor to chemotherapeutic agents. The resistance of tumors
occurs not only to a single cytotoxic drug used, but also occurs
as a cross-resistance to a whole range of drugs with diﬀerent
structures and cellular targets. This phenomenon is called mul-
tiple drug resistance (MDR). Once MDR appears, using high
doses of drugs to overcome resistance is ineﬀective, toxic eﬀects
appear and resistance are further stimulated. Multidrug resis-
tance (MDR) severely limits the eﬀectiveness of chemotherapy
in a variety of common malignancies and is responsible for the
overall poor eﬃcacy of cancer chemotherapy [1–5].Abbreviations:MDR, multidrug resistance; MRP, multidrug resistance
protein; ATP, adenosinetriphosphate; ABC, ATP-binding cassette;
TMD, transmembrane domains; P-gp, P-glycoprotein; MRP1, MDR
related protein; BCRP, breast cancer resistance protein; ABC-P, ABC
transporter in placenta; LRP, lung resistance-related protein; MVP,
major vault protein; CMOAT, canalicular multi-organic anion trans-
porter; CYP3A4, Cytochrome p450 3A4; SXR, steroid and xenobiotic
receptor; GC, glucosylceramide; GCS, glucosylceramide synthase;
GSH, glutathione; NAC, N-acetylcysteine; BSO, DL-buthionine
(S,R)-sulfoximine; HEK, human embryonic kidney; ROS, reactive
oxygen species
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doi:10.1016/j.febslet.2006.02.020The cytotoxic drugs that are most frequently associated with
MDR are hydrophobic, amphipathic natural products, such as
the taxanes (paclitaxel and docetaxel), vinca alkaloids (vinorel-
bine, vincristine, and vinblastine), anthracyclines (doxorubicin,
daunorubicin, and epirubicin), epipodophyllotoxins (etoposide
and teniposide), antimetabolites (methorexate, ﬂuorouracil,
cytosar, 5-azacytosine, 6-mercaptopurine, and gemcitabine)
topotecan, dactinomycin, and mitomycin C [4,6–8].
Overexpression of ATP-binding cassette (ABC) transporters
has been shown to be responsible for MDR [5]. Therefore eluci-
dation of the structure and function for each ABC transporter is
prerequisite for understanding how these transporters work and
for reversing MDR. One strategy for reversal of MDR in cells
expressing ABC transporters is combined use of anticancer
drugs with chemosensitizers. Inhibitors of ABC transporters
can be used to enhance oral bioavailability or the brain penetra-
tion of various drugs. Downregulation of MDR transporters
and circumventing MDR mechanisms are other approaches
to overcome MDR [3,5].2. ATP-binding cassette (ABC) transporters
Identifying the mechanisms leading to intrinsic or acquired
multidrug resistance (MDR) is important in developing more
eﬀective therapies [2]. The drug resistance in cancer cells often
results from elevated expression of particular proteins, such as
cell-membrane transporters, which can result in an increased
eﬄux of the cytotoxic drugs from the cancer cells, thus lower-
ing their intracellular concentrations [4,6,9]. The resistance
mechanism is called typical or classical MDR when overex-
pression of the membrane eﬄux pumps is involved in MDR
[5]. The classical MDR is due mostly to increased eﬄux pumps
in the cell membrane of cells pumping anticancer drugs out of
cells [1–3,5].
ATP-binding cassette (ABC) transporters are a family of
transporter proteins that contribute to drug resistance via
adenosinetriphosphate (ATP)-dependent drug eﬄux pumps
[10]. Up to date, more than 100 ABC transporters from pro-
karyotes to humans and 48 human ABC genes have been iden-
tiﬁed that share sequence and structural homology [4,5,10,11].
Not more than 10 of the ATP transporters are reported to con-
fer the drug-resistant phenotype [4,9]. The functions of 16
genes have been determined and 14 genes are related with sev-
eral diseases present in humans [5,11,12]. Although the resis-
tant proteins belong to the ABC superfamily, they are quite
diﬀerent with respect to gene locus, amino acid sequence,
structure and substrate [5]. ABC proteins are present in allblished by Elsevier B.V. All rights reserved.
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which contains a combination of conserved ABC and trans-
membrane domains (TMDs). In mammals, the functionally ac-
tive ABC proteins consist of at least four of such domains, two
TMDs and two ABCs. These domains may be present within
one polypeptide chain (full transporters), or within two sepa-
rate proteins (half-transporters). In this latter case, functional
ABC transporters need the dimerization of speciﬁc half-trans-
porters [13]. High sequence homology in the ATP-binding do-
mains known as nucleotide-binding folds allows identiﬁcation
and classiﬁcation of members of the ABC transporter family
[10]. These transporters use the energy released from the
hydrolysis of ATP to drive the transport of various molecules
across the cell membrane [4,11]. They are involved in the trans-
port of many substances, including the excretion of toxins
from the liver, kidneys, and gastrointestinal tract. It has been
increasingly recognized that transporter-mediated processes
signiﬁcantly modulate drug absorption, distribution, metabo-
lism and excretion [13]. In addition to their physiologic expres-
sion in normal tissues, many are over-expressed, in human
tumors [4]. There are seven subfamilies classiﬁed as ABC trans-
porters (ABC-A through ABC-G) that are expressed in both
normal and malignant cells [10]. A number of ABC transport-
ers and the chemotherapy drugs to which they have been
shown to confer resistance are listed in Table 1.3. Structure and function of ABC transporters
The most typical eﬄux pump in the cell membrane is P-gly-
coprotein (P-gp) having the molecular weight of 170 kDa, due
to the gene ampliﬁcation of the normal human gene, ABCB1
(MDR1) gene [5,10]. P-gp belongs to the ATP-binding cassette
(ABC) family of transporters. P-gp is responsible for trans-
porting various xenobiotics (not limited to anticancer drugs)
out of cells by using ATP. P-gp is glycosylated at the ﬁrst
extracellular loop and composed of 12 hydrophobic transmem-
brane domains (TMDs) and 2 nucleotide-binding domain
(NBD). One NBD connects two TMDs with a hydrophilic
NBD loop. TDMs form channels for substrate drugs, and ef-
ﬂux substrate drugs whereas NBDs are located in the interior
of cytoplasm, and participate in ATP binding and hydrolysis
[5,14]. Upon binding of ATP to the NBDs, P-gp undergoes
conformational changes and the TMDs reorganize into three
compact domains [5,15]. This reorganization opens the central
pore and allows transport of hydrophobic drugs (transport
substrates) directly from the lipid bilayer into the central pore
of the transporter [5,16].
The expression of P-gp is usually highest in tumors that are
derived from tissues that normally express P-gp, causing resis-
tance to some cytotoxic agents before chemotherapy is initi-
ated. In some tumors, the expression of P-gp may be low
before chemotherapy, but is induced after chemotherapy,
resulting in the development of MDR [4]. The failure of certain
chemotherapeutic agents are believed to link to the rapid
expression of P-gp [4,17]. For a long time, P-gp was believed
to be the only protein capable of conferring MDR in mamma-
lian tumor cells. However, several reports on human tumor cell
lines displaying MDR in the absence of P-gp overexpression,
together with studies that failed to detect P-gp in a variety of
human tumors pointed to the existence of other MDR confer-
ring proteins. In 1992, Susan Cole and Roger Deeley observedampliﬁcation and increased expression of a novel gene, the
MRP1 (ABCC1) (MDR related protein) gene in a non-P-gp
MDR cell line, namely a small-cell lung carcinoma cell line
[10,18]. Overexpression of MRPs, other ABC proteins, causing
MDR in mammalian cells has been also observed in several
other non-P-gp MDR cell lines. MRP1 has 3 membrane span-
ning domains, 2 nucleotide binding domains and extracellular
N-terminal. Both the structure and drug resistance spectra of
MRP1 and P-gp are similar except taxanes which are poor sub-
strates for MRP1. The second member of the multidrug resis-
tance protein (MRP) (ABCC) family is called the canalicular
multi-organic anion transporter (CMOAT, MRP2) which is
involved in bilirubin glucuronide transport and confers resis-
tance to MRP1 substrates and cisplatin. MRP3 is expressed
in liver and involved in the eﬄux of organic anions from the
liver into the blood in case of biliary obstruction. MRP4 and
MRP5 transport nucleosides and confer resistance to antiret-
roviral nucleoside analogs. MRP6 is a lipophilic anion pump
with a wide spectrum of drug resistance. Among the members
of MRP family, only MRP1 has been widely accepted to cause
clinical drug resistance [10].
The latest ABC transporter involved in MDR was cloned by
Ross and Doyle in 1998 from a mitoxantrone-resistant subline
of the breast cancer cell line MCF-7/Adr/Vp [19]. It is part of
ABCG subfamily. ABCG2 is the mitoxantrone resistance gene,
breast cancer resistance protein (BCRP), or ABC transporter
in placenta (ABC-P). BCRP is a half-transporter that probably
acts as a homo- or heterodimer in transporting cytotoxic
agents [10]. A 110 kDa protein originally named lung resis-
tance-related protein/major vault protein (LRP/MVP) is not
an ABC transporter, but a major vault protein which consti-
tutes >70% of subcellular ribonucleoprotein particles called
vaults. It is found in the cytoplasm and nuclear membrane,
not on the cell membrane like P-gp and MRP and excludes
drugs away from the nucleus into the cytoplasm. LRP is often
associated with vesicles and lysosomes and function with drug
sequestration into vesicles. After entering into vesicles, drugs
are excluded from the cell by exocytosis [8]. LRP overexpres-
sion predicts a poor response to chemotherapy in acute mye-
loid leukaemia and ovarian carcinoma [10].4. Development of MDR inhibitors
There are many studies to overcome MDR by inhibiting
MDR transporters, to suppress or circumvent MDR mecha-
nisms. The use of anticancer drugs that could escape from
the ABC transporters might be a solution to avoid drug resis-
tance. Anticancer drugs which are not the substrates of ABC
transporters are alkylating drugs (cyclophosphamide), antime-
tabolites (5-ﬂuorouracil), and the anthracycline modiﬁed drugs
(annamycin and doxorubicin-peptide) [5].
Another method to overcome resistance to anticancer drugs
is to administer compounds that would not be toxic them-
selves, but would inhibit ABC transporters [3,5]. The com-
pounds that would reverse resistance against anticancer
drugs are called MDR inhibitors, MDR modulators, MDR
reversal agents or chemosensitizers. They may modulate more
than one transporter [3,5].
Clinical trials helped to unravel the problems associated with
combination chemotherapy of anticancer drug(s) together with
an MDR inhibitor. The ﬁrst factor to be determined before
Table 1
Major ABC transporters associated with MDR, chemotherapy substrates and MDR inhibitors common other systematic substrates inhibitors
Common name Other names Systematic name Substrates Inhibitors
P-gp MDR1 ABCB1 Adriamycin Anthranilamide
Actinomycin-D Cyclosporine D
Bisantrene NSC-38721 (mitotane)
Daunorubicin Pipecolinate
Docetaxel Quinoline
Doxorubicin OC-144-093
Etoposide PSC-833 (valspodar)
Epirubicin MS-209
Homoharringtonine LY-335979 (zosoquidar)
Mitoxantrone XR-9576 (tariquidar)
Paclitaxel R-101933 (laniquidar)
Teniposide VX-710 (biricodar)
Topotecan GF-120918 (elacridar)
Vinblastine ONT-093
Vincristine Isothiocyanates
Vinorelbine Diallyl sulﬁde
VP-16 PK11195
Amooranin
siRNA
tRA 98006
Agosterol A
Flavonoids
MRP1 – ABCC1 Doxorubicin MS-209
Daunorubicin XR-9576 (tariquidar)
Etoposide VX-710 (biricodar)
Epirubicin Isothiocyanates
Methotrexate tRA 98006
Paclitaxel Agosterol A
Vincristine Rifampicin
Vinorelbine NSAIDs
MRP2 CMOAT ABCC2 Cisplatin XR-9576 (tariquidar)
CPT-11 (irinotecan) VX-710 (biricodar)
Doxorubicin Isothiocyanates
Etoposide tRA 98006
Methotrexate
Mitoxantrone
Vincristine
Vinblastine
SN-38
BCRP MXR1, ABC-P ABCG2 Bisantrene GF-120918 (elacridar)
Camptothecin tRA 98006
Daunorubicin Flavonoids
Doxorubicin Phytoestrogens
Epirubicin Imatinib mesylate
Flavopiridol Fumitremorgin C
Mitoxantrone TAG- 139
SN-38
Topotecan
CPT-11 (irinotecan)
Data from http://www.nutrigene.4t.com/humanabc.htm.
Liscovitch and Lavie [3]; Thomas and Coley [4]; Choi [5]; Ambudkar et al. [6], Stavrovskaya [8], Gottesman et al. [9]; Leonard et al. [10].
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protein involved in drug resistance and to utilize an anticancer
drug that would beneﬁt from inhibition of that transporter
protein. The anticancer drug(s) utilized should match the
transporter protein being inhibited. The second factor is to
monitor the plasma concentrations and in vivo eﬀectiveness
of the tested MDR inhibitor in order to verify that an eﬀective
inhibitory concentration was in fact achieved in vivo. The
pharmacokinetic interaction between the anticancer drug(s)
and the MDR inhibitor must be searched and avoided to pre-
vent a reduction in anticancer drug dosage.5. First-generation MDR modulators
Inhibiting P-gp and other ABC transporters has been exten-
sively studied for more than two decades [3,4]. Many agents of
diverse structure and function that modulate MDR have been
identiﬁed, including calcium channel blockers (e.g., verapa-
mil), calmodulin antagonists, steroidal agents, protein kinase
C inhibitors, immunosuppressive drugs (e.g., cyclosporine
A), antibiotics (e.g., erythromycin), antimalarials (e.g., qui-
nine), psychotropic phenothiazines and indole alkaloids
(e.g., ﬂuphenazine and reserpine), steroid hormones and
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(e.g., cremophorEL) and surfactants [4,20,21].
First-generation MDR drugs had other pharmacological
activities and were not speciﬁcally developed for inhibiting
MDR. Their aﬃnity was low for ABC transporters and neces-
sitated the use of high doses, resulting in unacceptable high tox-
icity which limited their application [4,7,20]. Clinical trials with
ﬁrst-generation MDR drugs failed for various reasons, often
due to side eﬀects [3,4,7,20,22]. Many of the ﬁrst-generation
chemosensitizers were themselves substrates for ABC trans-
porters and competed with the cytotoxic drugs for eﬄux by
the MDR pumps. Therefore, high serum concentrations of
the chemosensitizers were needed to produce suﬃcient intracel-
lular concentrations [6]. These limitations prompted the devel-
opment of new chemosensitizers that are more potent, less toxic
and selective for the P-gp and other ABC transporters [4,7].6. Second-generation MDR modulators
Second-generation chemosensitizers were designed to reduce
the side eﬀects of the ﬁrst generation drugs. Second-generation
MDRmodulators have a better pharmacologic proﬁle than the
ﬁrst-generation compounds, still they retain some characteris-
tics that limit their clinical usefulness. Co-administration of an
MDR modulator usually elevate plasma concentrations of an
anticancer drug by interfering its clearance or inhibiting its
metabolism and excretion, thus leading to unacceptable toxic-
ity that necessitates chemotherapy dose reductions in clinical
trials down to pharmacologically ineﬀective levels [3,4]. The
aﬃnity of second-generation MDR drugs towards ABC trans-
porters was too low to produce signiﬁcant inhibition of MDR
in vivo at tolerable doses [20].
Many of the anticancer drugs are substrates both for ABC
transporter proteins and for the cytochrome P450 isoenzyme
3A4. Most of the second-generation MDR chemosensitizers
are also substrates for cytochrome P450 3A4 and metabolized
by this enzyme [4]. The competition between anticancer agents
and MDR modulators for cytochrome P450 3A4 activity may
result in unpredictable pharmacokinetic interactions. Co-
administration of a MDR drug may signiﬁcantly elevate plas-
ma concentrations of an anticancer drug by interfering with
its clearance (e.g., via biliary elimination) or metabolism (e.g.,
via the cytochrome P450 system). This would increase the con-
centration of an anticancer drug leading to unacceptable side
eﬀects, necessitating dose reductions down to pharmacologi-
cally ineﬀective levels [3]. However since the pharmacokinetic
interactions between chemosensitizers and cytotoxic agents
are unpredictable, reducing the dose of a cytotoxic agent may
result in under- or over-dosing in patients [4,9,23]. The unpre-
dictable eﬀects of second-generation MDR modulators on
cytochrome P450 3A4-mediated drug metabolism limits the
use of these second-generation modulators in the treatment of
multidrug resistance.
ABC transporters have well deﬁned physiologic roles, often
involving the elimination of xenobiotics, in regulating the per-
meability of the central nervous system (blood–brain barrier),
the testes, and the placenta, thus preventing these systems from
being exposed to cytotoxic agents circulating in the blood [4].
Most of the second-generation MDR chemosensitizers are
substrates for ABC transporter family. Inhibition of these
transporters could lessen the ability of normal cells and tissuesto protect themselves from cytotoxic agents. Inhibition of non-
target transporters may enhance adverse eﬀects of anticancer
drugs. Side eﬀects due to modulation of MDR protein in nor-
mal tissues, especially blood–brain barrier should be moni-
tored carefully to avoid neurological responses. Because of
these problems, MDR inhibitors have not improved the thera-
peutic eﬃciency of anticancer drugs unless such agents lack
signiﬁcant pharmacokinetic interactions [3,24].7. Third-generation MDR modulators
Third-generation molecules have been developed to over-
come the limitations of the second generation MDR modula-
tors [4,7]. They are not metabolized by cytochrome P450
3A4 and they do not alter the plasma pharmacokinetics of
anticancer drugs. Third-generation agents speciﬁcally and po-
tently inhibit P-gp and do not inhibit other ABC transporters
[4]. None of the third-generation agents tested so far have
caused clinically relevant alterations in the pharmacokinetics
of the co-administered anticancer drugs. Because of their spec-
iﬁcity for P-gp transporters and lack of interaction with cyto-
chrome P450 3A4, third-generation P-gp inhibitors oﬀer
signiﬁcant improvements in chemotherapy without a need
for chemotherapy dose reductions [4].
Several such compounds are currently undergoing clinical
trials in several cancer types [3]. A non-immunosuppressive
cyclosporin D derivative (PSC-833; Valspodar; Novartis AG)
was the ﬁrst of these drugs to be studied [3]. Unfortunately,
further research with PSC-833 revealed pharmacokinetic
interactions with several anticancer drugs and inhibition of
non-MDR-related transporters [3]. Due to these results, devel-
opment of PSC-833 was discontinued [3].
Schering AG has developed a quinolone derivative MDR
modulator (MS-209). It is used in combination with the anti-
cancer drug (doxetaxel) in advanced solid (breast and lung
cancer) tumors [3].
One of the most promising third-generation P-gp inhibitors
is an anthranilamide derivative tariquidar (XR9576) which is
developed by NCI/Xenova/QLT Company [3]. In phase I
and II studies with paclitaxel and vinorelbine in ovarian can-
cer, tariquidar gave successful results and phase III trials have
been initiated with tariquidar in patients with non-small cell
lung cancer [3]. It binds speciﬁcally and non-competitively to
the P-gp pump with a high aﬃnity and potently inhibits the
activity of the P-gp transporter [3,4,24,25]. Tariquidar inhibits
the ATPase activity of P-gp [4,24]. Tariquidar is more potent
and its inhibitory action on the P-gp transporter pump lasts
longer in comparision to the eﬀects of ﬁrst- and second- gener-
ation P-gp modulators. In none of the clinical trials, tariquidar
caused alterations in the pharmacokinetics of the coadminis-
tered cytotoxic agents such as paclitaxel, vinorelbine, or doxo-
rubicin in patients with solid tumors [3,4]. This allows the use
of standard doses of these chemotherapeutic agents without
the need for dose reduction.
Vertex Pharmaceuticals Inc. developed a pipecolinate analog,
VX-710 (biricodar, Incel) which is a high-aﬃnity P-gp andMRP
inhibitor. VX-710 has no pharmacokinetic interactions with
doxorubicin and is undergoing trials in solid tumors [3].
Laniquidar (R101933; NCI/EORTC Inc.) and the substi-
tuted diarylimidazole ONT-093 (Ontogen Inc.) are among
the third generation P-gp inhibitors. They have a high po-
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diverse chemical structures and origins [4,24,26]. R101933
and ONT-093 were shown to inhibit P-gp pump with no ef-
fect on the pharmacokinetics of docetaxel and paclitaxel
[3,4,24,26].
The cyclopropyldibenzosuberane modulator LY335979
developed by Eli Lilly Inc. was shown to competitively inhibit
the binding of vinblastine to P-gp [3,4]. LY335979 showed no
signiﬁcant pharmacokinetic interactions with doxorubicin, eto-
poside, daunorubicin, vincristine, or paclitaxel in both solid
and hematologic malignancies [4,27,28].
Mitotane is not a typically third-generation drug and does
not inhibit P-gp. It was utilized for treatment of adrenocortical
carcinoma in combination with anticancer drugs [3]. Glaxo-
SmithKline developed GF-120918 (elacridar) which inhibits
P-gp and BCRP and shows no pharmacokinetic interactions
with doxorubicin. Annamycin (Antigenics Inc.) is not a P-gp
inhibitor, but an anthracycline that is not transported by
P-gp [3].
Clinical trials with these new third-generation agents are
ongoing with the aim for a longer survival in cancer patients.
This eﬀort continues, but none of them has found a general
clinical use so far.8. Novel approaches to struggle with MDR mechanisms
The diﬃculties encountered with MDR inhibitors have led
several alternative approaches to MDR therapy. These ap-
proaches can be divided in two groups. One group of studies
consists of trials designed to inhibit MDR mechanisms in no-
vel ways and the other group focuses on trials to circumvent
MDR mechanisms [3].
There are several approaches to inhibit mechanisms involved
in regulation of MDR transporters. MDR protein gene expres-
sion in tumor cells is induced upon treatment with cytotoxic
drugs, whereas this gene expression is inhibited by several
pharmacological inhibitors that aﬀect the signaling pathways.
It was demonstrated that taxol stimulated MDR1 and cyto-
chrome p450 3A4 (CYP3A4) gene expression via its direct
interaction with and activation of the nuclear steroid and
xenobiotic receptor (SXR) which led to increased drug resis-
tance and faster drug clearance [3]. Hence, antagonists of the
nuclear steroid and xenobiotic receptor may be utilized in con-
junction with anticancer drugs to cope with the induction of
MDR1 and CYP3A4 [3].
Recent advances in antisense oligonucleotide technologies
suggest an alternative and more speciﬁc way to cope with
MDR than the use conventional MDR inhibitors [29]. Down-
regulation of ABC transporter proteins and enzymes involved
in cancer cell resistance using antisense oligonucleotides may
provide an eﬃcient approach to overcome MDR.
Recent studies clariﬁed the role of ceramide as a second mes-
senger in cellular apoptotic signaling events [30]. A decrease in
ceramide production increases cellular resistance to apoptosis.
It was demonstrated that glucosylceramide (GC), a simple gly-
cosylated form of ceramide which results from elevated GlcCer
synthase activity accumulates in multidrug resistant cancer
cells and tumors derived from patients who are less responsive
to chemotherapy [31–33]. Overexpression of recombinant Glc-
Cer synthase (GCS) confers resistance to adriamycin and to
ceramide in GlcCer synthase-transfected human breast cancercells, suggesting that drug resistance is related to stimulation of
glucosylation of ceramide and the resultant inhibition of drug-
induced apoptotic signaling [30,34]. Blocking the glycosylation
of ceramide has been shown to increase cancer cell sensitivity
to cytotoxics [35–37]. Drug combinations that enhance cera-
mide generation and limit glycosylation have been shown to
enhance eﬀectiveness of chemotherapy by inducing apoptosis
in cancer cell models [36,37]. The role of GlcCer synthase in
drug resistance was demonstrated directly by antisense sup-
pression of GlcCer synthase expression in MDR cells [30].
Downregulation of ceramide glycosylation using GCS anti-
sense in adriamycin-resistant breast cancer cells restored cell
sensitivity to adriamycin [30]. In another study, a novel ami-
no-ceramide analog was shown to inhibit GlcCer synthase
and thereby elevate ceramide production in MDR cells,
enhancing drug-induced apoptosis [3]. These ﬁndings assign
biological signiﬁcance to ceramide metabolism and provides
a promising approach to struggle with drug resistance. These
results indicate that GlcCer synthase contributes to drug resis-
tance in MDR cells by attenuating drug-induced formation of
apoptotic ceramide and suggest that GlcCer synthase may rep-
resent a novel drug target in cancer MDR [38].
Living cells needs MDR mechanisms for their normal phys-
iology. Therefore, researchers prefer to circumvent rather than
directly inhibit MDR mechanisms [3]. Developing anticancer
drugs that are poor substrates for ABC transporters might
be a good strategy in cancer therapy. Another approach is to
prevent formation of new blood vessels which is called angio-
genesis. For a long time, it is believed that tumors induce angi-
ogenesis to provide an adequate blood supply for oxygen and
nutrients. New vessel formation are inhibited using anti-angio-
genic factors. However, most of the anti-angiogenic factors
have other eﬀects on the cells which limit their treatment.
A major dose-limiting toxicity factor for anticancer drugs is
to avoid complete eradication of bone marrow stem cells. Got-
tesman et al. produced multidrug resistant bone marrow cells
by transfecting them with vectors carrying the MDR1 cDNA.
This procedure allowed them to apply a chemotherapeutic reg-
imen at otherwise unacceptable doses, and thus overcoming
MDR [3,9].
Recent studies suggest that a mutant ABCG2 protein is an
ideal candidate for human stem cell protection and for use
as a selectable marker in gene therapy [13]. The cDNA encod-
ing this protein is relatively small (about 2 kb) and the active
dimer is spontaneously formed in the overexpressing cells.
Since the R482G variant of ABCG2 has diﬀerent substrate
speciﬁcity than the wild-type protein, this mutant has a special
advantage in gene therapy applications [13].
A novel procedure for circumventing MDR mechanisms, in-
volves the use of an apoptosis inducing monoclonal antibody
directed against the CD20 receptor. Induction of apoptosis
in drug sensitive cells improves the eﬃcacy of chemotherapy
[39].
The exact mechanism of MRP1 involved multidrug resis-
tance has not been clariﬁed yet, though glutathione (GSH) is
likely to have a role for the resistance to occur. N-acetylcyste-
ine (NAC) is a pro-glutathione drug. DL-Buthionine (S,R)-sul-
foximine (BSO) is an inhibitor of GSH synthesis. Recently, we
investigated the eﬀect of NAC and BSO on MRP1-mediated
vincristine and doxorubicine resistance in human embryonic
kidney (HEK293) and its MRP1 transfected 293MRP cells
[1,2]. Human embryonic kidney (HEK293) cells were transfec-
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were incubated with vincristine and doxorubicine in the pres-
ence or absence of NAC and/or BSO. N-acetylcysteine in-
creased the resistance of both cells against vincristine and
doxorubicine. In contrast, BSO decreased NAC-enhanced
MRP1-mediated resistance, indicating that induction of
MRP1-mediated resistance depends on GSH. Our results indi-
cate that NAC and BSO have opposite eﬀects in MRP1 med-
iated vincristine and doxorubicine resistance and BSO seems a
promising chemotherapy improving agent in MRP1 over-
expressing tumor cells.
A number of drugs used in cancer chemotherapy induce oxi-
dative stress by generation of reactive oxygen species (ROS).
Recent studies suggest that ROS formation caused by these
drugs might be an alternative mechanism for their cytotoxic ef-
fect via inducing apoptosis. Since ROS are proposed to play a
role in drug-induced apoptosis, one might suspect that antiox-
idants would inhibit the ability of chemotherapeutic drugs to
induce ROS generation and antioxidant supplementation
should be avoided in cancer patients in order not to prevent
chemotherapy induced apoptosis. Chemopreventive ap-
proaches utilizing non-toxic agents aimed at both minimizing
ROS formation and inducing apoptosis in tumor cells seem
attractive.
In a recent study it was demonstrated that novel catechin
derivatives obtained from grape procyanidins scavenge free
radicals, and reduce cell viability in A375 and M21 mela-
noma cells [40]. In particular, 4b-(S-cysteinyl) epicatechin 3-
O-gallate has a free radical scavenging capacity and causes
a signiﬁcant S-phase cell-cycle arrest in both cell lines at
doses higher than 100 lM. The gallate derivative also induces
apoptosis in melanoma cells triggering nuclear condensation
and fragmentation, which is conﬁrmed by DNA laddering.
In contrast, it does not induce apoptosis in keratinocytes
(HaCaT) [40].
An impressive body of information exists on the antitumor
action of plant ﬂavonoids [41]. In vitro work has concen-
trated on the direct and indirect actions of ﬂavonoids on tu-
mor cells, and has found a variety of anticancer eﬀects such
as cell growth and kinase activity inhibition, apoptosis induc-
tion, suppression of the secretion of matrix metalloprotein-
ases and tumor invasive behavior. Furthermore, some
studies have reported the impairment of in vivo angiogenesis
by dietary ﬂavonoids. Experimental animal studies indicate
that certain dietary ﬂavonoids possess antitumor activity.
The hydroxylation pattern of the B ring of the ﬂavones
and ﬂavonols, such as luteolin and quercetin, seems to criti-
cally inﬂuence their activities, especially the inhibition of pro-
tein kinase activity and antiproliferation [41]. In our recent
study, the ﬂavonoid, Quercetin (3,3 0,4 0,5,7-pentahydroxyﬂav-
one) did not inhibit ROS generation, and enhanced cytotox-
icity of Topotecan in two human breast cancer cell lines,
MCF-7 and MDA-MB-231 [42,43]. The diﬀerent mechanisms
underlying the potential anticancer action of plant ﬂavonoids
await further elucidation. Further in vivo studies of these
bioactive constituents is necessary in order to develop ﬂavo-
noid-based anticancer strategies. These studies demonstrate
that antioxidants may have diverse eﬀects in the cytotoxicity
of chemotherapeutic drugs depending on their other pharma-
cological properties which may predominate their antioxidant
eﬀects.9. Conclusion
In the last two decades, search for eﬀective and clinically
applicable MDR therapies took place to clarify the mecha-
nisms underlying MDR and to develop agents either to inhibit
or circumvent MDR mechanisms. Novel approaches are being
devised to overcome MDR mechanisms. In spite of advances
in cancer chemotherapy and developing a few good candidates
to modulate MDR, we are still too far to conclude that these
agents could be applied clinically. We may expect that ad-
vances in cancer chemotherapy will continue and knowledge
to achieve eﬀective chemotherapy will increase exponentially
in the not too distant future.
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